Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAP NASDAQ:AKYA NASDAQ:CNTB OTCMKTS:NICXF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.27-2.1%$0.27$0.20▼$1.48$72.70M2.181.63 million shs314,641 shsAKYAAkoya Biosciences$1.29$1.22$0.93▼$3.42$64.44M1.36408,569 shsN/ACNTBConnect Biopharma$1.52+32.2%$0.90$0.51▼$1.60$63.90M-0.261,110 shs804,408 shsNICXFNicox$0.25$0.25$0.25▼$0.28$17.23M0.29N/AN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics-0.54%+9.28%-1.08%+23.39%-76.95%AKYAAkoya Biosciences0.00%-5.77%-3.01%+4.03%-37.98%CNTBConnect Biopharma+5.64%+1.32%+44.65%+84.00%-10.16%NICXFNicox0.00%0.00%0.00%0.00%-43.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAPAdaptimmune Therapeutics2.1545 of 5 stars3.14.00.00.02.40.80.0AKYAAkoya Biosciences1.9998 of 5 stars3.03.00.00.01.61.70.6CNTBConnect Biopharma3.0017 of 5 stars3.53.00.00.02.62.50.6NICXFNicoxN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 2.29Hold$1.35403.23% UpsideAKYAAkoya Biosciences 2.00Hold$2.5194.26% UpsideCNTBConnect Biopharma 3.00Buy$7.00360.53% UpsideNICXFNicox 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NICXF, AKYA, ADAP, and CNTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025ADAPAdaptimmune TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$1.50 ➝ $0.506/12/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$7.005/19/2025AKYAAkoya BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.80 ➝ $1.085/14/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.005/14/2025ADAPAdaptimmune TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.464/29/2025AKYAAkoya BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$3.50 ➝ $1.804/14/2025AKYAAkoya BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.40 ➝ $1.654/11/2025ADAPAdaptimmune TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$178.03M0.40N/AN/A$0.05 per share5.37AKYAAkoya Biosciences$79.96M0.81N/AN/A$0.15 per share8.60CNTBConnect Biopharma$26.03M3.24N/AN/A$1.67 per share0.91NICXFNicox$5.52M3.12N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$70.81M-$0.27N/AN/AN/A-38.91%-163.73%-23.65%8/11/2025 (Estimated)AKYAAkoya Biosciences-$55.37M-$0.97N/AN/AN/A-59.44%-487.85%-35.86%8/4/2025 (Estimated)CNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/A9/5/2025 (Estimated)NICXFNicox-$29.25MN/A0.00∞N/AN/AN/AN/A7/16/2025 (Estimated)Latest NICXF, AKYA, ADAP, and CNTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025AKYAAkoya Biosciences-$0.22N/AN/AN/A$18.10 millionN/A5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/A5/13/2025Q1 2025ADAPAdaptimmune Therapeutics-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million5/12/2025Q1 2025AKYAAkoya Biosciences-$0.29-$0.32-$0.03-$0.32$20.19 million$16.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/AAKYAAkoya BiosciencesN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/ANICXFNicoxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune Therapeutics4.242.021.79AKYAAkoya Biosciences10.120.610.40CNTBConnect Biopharma0.0110.2510.25NICXFNicoxN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%AKYAAkoya Biosciences79.42%CNTBConnect Biopharma58.72%NICXFNicoxN/AInsider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.74%AKYAAkoya Biosciences7.30%CNTBConnect Biopharma22.60%NICXFNicoxN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million231.28 millionOptionableAKYAAkoya Biosciences9049.95 million46.31 millionOptionableCNTBConnect Biopharma11055.56 million43.00 millionOptionableNICXFNicox2868.92 millionN/ANot OptionableNICXF, AKYA, ADAP, and CNTB HeadlinesRecent News About These CompaniesNicox S.A. (NICXF) Stock Price, Quote, News & AnalysisJuly 1, 2025 | seekingalpha.comNicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertensionJune 30, 2025 | ophthalmologytimes.comONicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical TrialJune 30, 2025 | manilatimes.netMNicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representativeJune 6, 2025 | santelog.comSNICOX SA: Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in JapanMay 27, 2025 | finanznachrichten.deNicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in JapanMay 27, 2025 | finance.yahoo.comNicox releases results from Whistler phase 3b trial in IOP lowering eye dropsMay 15, 2025 | ophthalmologytimes.comONicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma TrialMay 14, 2025 | finance.yahoo.comNicOx S.A.May 10, 2025 | barrons.comNicox Provides Full Year 2024 Financial ResultsApril 30, 2025 | finance.yahoo.comNicox announces last patient completed final visit in Whistler Phase 3b clinical trialMarch 24, 2025 | ophthalmologytimes.comONICOX SA: Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma TrialMarch 19, 2025 | finanznachrichten.deNicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma TrialMarch 19, 2025 | markets.businessinsider.comNicox presents new analysis from the NCX 470 Mont Blanc trialMarch 7, 2025 | thepharmaletter.comTNICOX SA: Nicox Extends Cash Runway into Q4 2025March 6, 2025 | finanznachrichten.deNicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development UpdateMarch 3, 2025 | markets.businessinsider.comNicox Announces Scientific Presentation and Conference Attendance in H1 2025January 29, 2025 | markets.businessinsider.comNiconico's Mature Illustration Service Niconico Shunga to End ServiceJanuary 18, 2025 | animenewsnetwork.comANiconico Shunga Latest Japanese Retailer to Shutter Because of “Current Social Environment”January 18, 2025 | otakuusamagazine.comOJapanese publisher Kadokawa paid $3 million to Russia-linked hacker group after cyberattackDecember 12, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNICXF, AKYA, ADAP, and CNTB Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.27 -0.01 (-2.08%) Closing price 04:00 PM EasternExtended Trading$0.27 +0.00 (+0.15%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Akoya Biosciences NASDAQ:AKYA$1.29 0.00 (0.00%) As of 07/8/2025Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.Connect Biopharma NASDAQ:CNTB$1.52 +0.37 (+32.17%) Closing price 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.33%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Nicox OTCMKTS:NICXF$0.25 0.00 (0.00%) As of 07/8/2025Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
